ABSENCE OF PHARMACOKINETIC INTERACTION OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B‐CELL NON‐HODGKIN'S LYMPHOMA (INHL)Andres Forero‐Torres, Sumit Madan, Michelle Quinlan et al.|Hematological Oncology|2017Cited by 0
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's LymphomaAndres Forero‐Torres, Sumit Madan, Jason C. Chandler et al.|Clinical Pharmacology in Drug Development|2022Cited by 0
632eP Prevalence of ESR1 mutations in ER+/HER2- advanced breast cancer (aBC) patients treated with everolimus after CDK4/6 inhibitorsFrançois C. Bocquet, Alice Rudolph, Manuel Alva Bianchi et al.|Annals of Oncology|2025Cited by 0